RESEARCH PEPTIDE FUNDAMENTALS / FAQ
Questions Readers Bring to This Shelf
Direct, citation-anchored answers drawn from the published research on all four compounds.
What does BPC-157 do in the body?
In animal studies, BPC-157 is best characterized as pro-angiogenic — it up-regulates the VEGFR2 receptor and promotes blood-vessel growth through the VEGFR2-Akt-eNOS signaling pathway, which is the mechanism most consistently linked to its tissue-repair effects [4]. It has also shown gastric-ulcer-healing effects in rats, accelerating rebuilding of the stomach lining [5]. In humans, the evidence is far more limited: a 2025 pilot found intravenous BPC-157 up to 20 mg well tolerated in two adults with no measurable safety-biomarker changes, but this is a safety signal from two people, not proof of any effect [1].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone and does not act through the growth-hormone axis in the way growth hormone itself does. One proposed mechanism does involve growth-hormone-receptor sensitization in tendon fibroblasts specifically, which is thought to support tendon repair, but this is a localized sensitization effect in one tissue type, not a systemic hormonal action [4]. BPC-157's primary documented mechanism is angiogenesis via VEGFR2, an entirely different pathway from growth-hormone signaling.
Does BPC-157 work immediately?
There is no controlled human trial measuring onset of effect for BPC-157, so this cannot be answered from clinical data. In research-use communities, people describe tendon and joint improvements building over one to three weeks rather than appearing immediately, and describe this as anecdotal, not clinical evidence. The published human literature — currently three small pilot reports — has not established a timeline for any effect [2].
Does BPC-157 damage the liver?
The published literature reviewed for this site does not report liver injury associated with BPC-157. The 2025 human safety pilot found no measurable changes in hepatic biomarkers in the two adults studied [1]. That said, the overall human safety dataset is extremely small — three pilot reports as of 2025 — so an uncommon or rare effect could exist without yet having been detected. A 2025 review explicitly recommends treating BPC-157 as investigational given how limited the human safety data remain [2].
What is NAD+ supplement used for?
NAD+ supplements, and their precursors NMN and nicotinamide riboside, are marketed primarily around cellular energy metabolism and the biology of aging, based on the fact that tissue NAD+ levels decline with age [9]. Controlled human trials confirm that oral NMN and NR reliably raise blood NAD+ in a dose-dependent way [7][10]. A 2023 trial also found NMN supplementation improved walking distance and quality-of-life scores versus placebo in middle-aged adults [7]. Whether raising NAD+ produces broader clinical benefits beyond these measured outcomes remains an open, actively studied question [6].
What is the downside of taking NAD+?
The clearest downside documented in the literature is a gap between demonstrated effects: blood NAD+ elevation is well established, but clinical-outcome efficacy is still limited according to a 2025 review [6]. IV or injectable NAD+ wellness therapy in particular rests on less controlled evidence than oral precursor trials, can cause discomfort, flushing, or nausea if infused too quickly, and compounded injectable NAD+ has been subject to an FDA Class I recall for bacterial endotoxin contamination. There is also a theoretical concern that boosting NAD+ could support the metabolism of an existing cancer, since NAD+ is used by proliferating cells generally.
Is it safe to take NAD daily?
This site does not recommend any dose or schedule for any compound. What the published trials show is that oral NMN at doses up to 900 mg/day for 60 days, and nicotinamide riboside at doses up to 1000 mg/day for eight weeks, were both well tolerated in controlled human trials with no significant difference in adverse events versus placebo [7][10]. Those findings describe what was studied in specific trial populations over specific durations — they are not a safety guarantee for any individual, and IV/injectable delivery of NAD+ carries separate and less-studied risks.
Does NAD+ cause weight gain?
The controlled trials reviewed for this site do not report weight gain as an outcome of NAD+ precursor supplementation. A 2021 trial of NMN in prediabetic postmenopausal women found no change in body composition over 10 weeks despite an improvement in muscle insulin sensitivity [8]. No study in this corpus links NAD+ or its precursors to weight gain; if anything, the metabolic-function angle these compounds are studied for runs in the opposite direction, though the evidence for a weight effect either way is not established.
What is PT-141?
PT-141 is the research name for bremelanotide, a synthetic cyclic peptide that activates melanocortin receptors (chiefly MC4R) concentrated in the brain's hypothalamus and limbic system. It is FDA-approved as an injectable prescription medicine for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [15]. Its mechanism is central — acting on brain circuitry tied to desire and motivation — rather than peripheral or vascular [12].
What does the PT-141 peptide do?
PT-141 activates central melanocortin receptors, chiefly MC4R, in hypothalamic circuits linked to sexual desire and motivation. A 2022 fMRI study in women with HSDD found that MC4R agonism significantly increased sexual desire for up to 24 hours and measurably altered brain processing of erotic stimuli [12]. In Phase 3 trials, it produced a statistically significant improvement in desire and reduction in desire-related distress compared with placebo over 24 weeks in the approved population [13].
What is PT-141 used for?
PT-141, as the FDA-approved drug bremelanotide, is used specifically for hypoactive sexual desire disorder in premenopausal women, dosed as a 1.75 mg subcutaneous injection taken as needed, with a labeled maximum of one dose per 24 hours and no more than eight doses per month [15]. Use in men, in postmenopausal women, or for general sexual-performance enhancement is off-label and is not what the approved trials studied — the Phase 3 evidence base applies only to the labeled population [13][15].
What does a GHK-Cu peptide do?
GHK-Cu is a copper-binding tripeptide studied mainly for its effects on skin structure. At the cellular level, it stimulates dermal fibroblasts to produce more collagen, elastin, and glycosaminoglycans, while also rebalancing the enzymes that break matrix proteins down [19][21]. Topical trials report increased procollagen synthesis (70% of treated subjects in one comparison, versus 50% for vitamin C and 40% for retinoic acid), and a 2016 randomized trial of a related formulation found a significant increase in hair count over placebo [16][18].
What is GHK-Cu and how does it work?
GHK-Cu is a naturally occurring three-amino-acid peptide (glycine-histidine-lysine) chelated to a copper ion, released in the body when type I collagen breaks down. It works partly through the bound copper — which enables the enzyme lysyl oxidase to cross-link collagen and elastin, and gives the complex antioxidant activity — and partly as a direct signaling molecule, altering expression of roughly 31.2% of human genes at a 50%-or-greater change threshold, including strong activation of DNA-repair, antioxidant, and protein-quality-control pathways [17].
Is GHK-Cu peptide really anti-aging?
GHK-Cu has real, published human evidence for specific, measurable skin outcomes — increased collagen synthesis, reduced fine-line and wrinkle depth in controlled comparisons, and improved hair count in a related formulation [16][18][19]. Plasma GHK also declines measurably with age, from about 200 ng/mL at age 20 to about 80 ng/mL by age 60, which is the basis for the anti-aging framing [19]. Whether this adds up to a general "anti-aging" effect beyond these specific, documented, mostly topical skin outcomes is a broader claim than the controlled evidence directly supports, and the strongest human data remains concentrated in small trials.
What is the difference between GHK and GHK-Cu?
GHK is the plain three-amino-acid tripeptide (glycine-histidine-lysine) on its own. GHK-Cu is that same tripeptide bound to a copper ion. This distinction matters because most of GHK-Cu's documented tissue-remodeling activity depends specifically on the copper being properly bound — the plain GHK peptide without copper does not reproduce key effects, such as stimulating collagen-remodeling enzymes, in cell studies. The two are frequently conflated in casual discussion, but the published literature treats copper coordination as functionally required for most of the reported bioactivity.